Acute Respiratory Distress Syndrome Subphenotypes beyond the Syndrome: A Step toward Treatable Traits?

Few trials of pharmacological interventions in critical care show benefit despite decades of laboratory-based and translational research dedicated to identifying mechanisms responsible for critical illness (1). This reality has prompted us to consider the limitations of our current definitions of critical illness syndromes. Syndromes such as acute respiratory distress syndrome (ARDS) and sepsis are defined based on clinical criteria that yield little insight into their underlying biology. This syndromic approach to disease classification has led to trial designs that target heterogeneous populations, which may explain why treatments have been unsuccessful. The identification of biologically distinct subphenotypes in ARDS (2, 3), sepsis, and acute kidney injury, which have divergent outcomes and may respond differently to randomly allocated therapies (2, 4–7), may point toward an alternative approach to testing pharmacological therapies. These subphenotypes tend to be defined by biomarkers that are agnostic to syndromic diagnosis within critical illness, suggesting mechanistic pathways may be conserved across these syndromes. Interestingly, similarities between subphenotypes identified using varying methods for phenotype allocation and in different syndromes have emerged (7, 8). Indeed, ARDS subphenotypes with distinct clinical trajectories have also been identified in patients with coronavirus disease (COVID-19) (9). These findings led to the hypothesis that there may be host-response subphenotypes of critical illness, which might also be termed “treatable traits,” that are independent of syndromic definitions (Figure 1). If this hypothesis is correct, our approach to clinical trials premised on those syndromic definitions should be reevaluated. In this issue of the Journal, Heijnen and colleagues (pp. 1503–1511) provide the most compelling evidence to date supporting the concept that treatable traits in critical illness are independent of syndromic diagnosis (10). In a retrospective analysis of a large cohort of mechanically ventilated patients (n5 2,499), they used previously described parsimonious models for subphenotype allocation for their reactive and uninflamed ARDS subphenotypes (cluster-derived, using IL-6, IFN-g, ANG1/2, and PAI-1) (3) and for the hyperinflammatory and hypoinflammatory subphenotypes (latent class analysis [LCA]-derived, using IL-8, protein C, and bicarbonate) (11) to demonstrate that these classifier methods also provide prognostic enrichment in a non-ARDS population (n5 1,825). Regardless of ARDS diagnosis, the reactive and hyperinflammatory subphenotypes retained their associations with increased ICUmortality, increased 30-day mortality, and lower probability of successful extubation. In keeping with previous ARDS studies, this study demonstrates that in univariable analysis, the reactive and hyperinflammatory subphenotypes were the strongest predictors of ICUmortality in patients without ARDS(hazard ratio, 2.43; 95% confidence interval [CI], 1.90–3.11; P, 0.001; and hazard ratio, 2.54; 95% CI, 2.00–3.24; P, 0.001, respectively). These subphenotypes retained their association with mortality even when adjusted for APACHEIV score, demonstrating prognostic value independent of severity of illness. A subset of patients (n5 719) had leukocyte gene expression profiles examined by microarray. Principal component analysis revealed that members of the same cluster-derived and LCA-derived subphenotypes grouped together regardless of the presence of ARDS, suggesting that the transcriptome is conserved within these subgroups across syndromic definitions and providing further evidence that the biology of these subphenotypes is fundamentally distinct. These data have important implications. First, they suggest that the subphenotypes identified in ARDS to date (e.g., reactive vs. uninflamed and hypervs. hypoinflammatory) may be translatable to patients without ARDS. Furthermore, independently described subphenotypes have significant overlap, and analogous clusterand LCA-derived subphenotypes (hyperinflammatory and reactive; hypoinflammatory and uninflamed) demonstrated similar blood leukocyte gene expression profiles. This latter finding suggests convergence at a common biological signal, further increasing confidence that these subphenotypes represent a generalizable and reproducible finding. Despite the strength of this data, some limitations should be considered. The study population consisted solely of mechanically ventilated patients, and there was a bias in biomarker data availability toward those patients with definite or probable infection, who have a high risk of developing ARDS. Subphenotyping methods developed in ARDS may therefore be more translatable to this population rather than a broader population. Furthermore, classification was accomplished using parsimonious models rather than the gold-standard cluster analysis or LCA. Despite the strong concordance of these models with gold standard (AUC5 0.94; 95% CI, 0.92–0.95 for LCAderived subphenotypes; AUC5 0.98; 95% CI, 0.97–0.99 for cluster-derived subphenotypes) (3, 11), without de novo cluster analysis or LCA, these results cannot provide statistical evidence that a two subphenotype approach is the most robust approach to subdivision in patients without ARDS. These results imply that treatments that are found to work in ARDS-specific subphenotypes might be translatable to a broader population of patients. In a post hoc analysis of the HARP-2 clinical trial of simvastatin in ARDS, which showed no overall benefit, the LCA-derived hyperinflammatory subphenotype had improved 28-day survival with simvastatin versus placebo (5). Although prospective validation is needed, the results presented here suggest that “hyperinflammatory” patients without ARDSmight also benefit from simvastatin. Unfortunately, the ability to prospectively phenotype critically ill patients on ICU admission remains a This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).